Amphastar Pharmaceuticals Inc

Amphastar Pharmaceuticals’ Q3 2025 earnings beat estimates, driven by double‑digit BAQSIMI growth and a new FDA‑approved iron sucrose injection, positioning the company for continued upside.

Amphastar Pharmaceuticals Inc. exceeded Q1 earnings expectations, reporting $170.5 million in net revenues and highlighting its strategic initiatives aimed at sustaining growth in the pharmaceutical industry.